Publicação científica trimestral do CREMERJ - número 4 - 2022

44 Nefrotoxicidade – Aspectos Básicos Caroline Azevedo Martins e Mauricio Younes-Ibrahim Med. Ciên. e Arte , Rio de Janeiro, v.1, n.4, p.31-44, out-dez 2022 32. Tziakas D, Chalikias G, Stakos D, et al. Validation of a new risk score to predict contrast-induced nephropathy after percutaneous coronary intervention. Am J Cardiol. 2014;113(9):1487-93. DOI:10.1016/j. amjcard.2014.02.004 33. Tziakas D, Chalikias G, Stakos D, et al. Development of an easily applicable risk score model for contrast- induced nephropathy prediction after percutaneous coronary intervention: a novel approach tailored to current practice. Int J Cardiol. 2013;163(1):46-55. DOI: 10.1016/j.ijcard.2011.05.079.  34. Sgura FA, Bertelli L, Monopoli D, et al. Mehran contrast-induced nephropathy risk score predicts short- and long-term clinical outcomes in patients with ST-elevation-myocardial infarction. Circ Cardiovasc Interv. 2010;3(5):491-8. DOI: 10.1161/CIRCINTERVENTIONS.110.955310.  35. Wi J, Ko YG, Shin DH, et al. Prediction of contrast-induced nephropathy with persistent renal dysfunction and adverse long-term outcomes in patients with acute myocardial infarction using the mehran risk score. Clin Cardiol. 2013;36(1):46-53. DOI: 10.1002/clc.22060.  36. INTERNATIONAL HUMAN GENOME SEQUENCIN CONSORTIUM - Initial sequencing and analysis of the human genome. Nature 409: 860-921, 2001. DOI: 10.1038/35057062. 37. INTERNATIONAL SNP MAP WORKING GROUP - A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409: 928-33, 2001. DOI: 10.1038/35057149. 38. Cargill, M. et al. - Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nature Genet 22: 231-8, 1999. DOI: 10.1038/10290 39. Zaidan M, Lescure FX, Brocheriou I, et al. Tubulointerstitial nephropathies in HIV-infected patients over the past 15 years: a clinico-pathological study. Clin J American Soc Nephrol. 2013;8(6):930–8. DOI: 10.2215/CJN.10051012 40. Xie H, Chen H, Hu Y, et al. Clindamycin-induced acute kidney injury: large biopsy case series. Am J Nephrol. 2013;38(3):179–83. DOI: 10.1159/000354088.  41. Bunchman TE, Valentini RP, Gardner J, et al. Treatment of vancomycin overdose using high-efficiency dialysis membranes. Pediatr Nephrol. 1999;13(9):773–4. DOI: 10.1007/s004670050697.  42. Hwang YJ, Dixon SN, Reiss JP, et al. Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults: a population-based cohort study. Ann Intern Med. 2014;161(4):242–8. DOI: 10.7326/M13-2796. 43. Gandhi S, Fleet JL, Bailey DG, et al. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. JAMA. 2013;310(23):2544–53. DOI: 10.1001/jama.2013.282426. 44. Beger RD, Sun J, Schnackenberg LK. Metabolomics approaches for discovering biomarkers of drug- induced hepatotoxicity and nephrotoxicity. Toxicol Appl Pharmacol. 2010;243(2):154–66. DOI: 10.1016/j. taap.2009.11.019.  45. Betton GR, Kenne K, Somers R, Marr A. Protein biomarkers of nephrotoxicity; a review and findings with cyclosporin A, a signal transduction kinase inhibitor and N-phenylanthranilic acid. Cancer biomark. 2005;1(1):59–67. DOI: 10.3233/CBM-2005-1107.  46. Boudonck KJ, Mitchell MW, Nemet L, et al. Discovery of metabolomics biomarkers for early detection of nephrotoxicity. Toxicol Pathol. 2009;37(3):280–92. DOI: 10.1177/0192623309332992.  47. Davis JW, Kramer JA. Genomic-based biomarkers of drug-induced nephrotoxicity. Expert Opin Drug Metab Toxicol. 2006;2(1):95–101. DOI: 10.1517/17425255.2.1.95